Replies to post #179714 on Avid Bioservices Inc (CDMO)

[biopharm]

Ambit / Peregrine collaboration.... trying to pull a needle from a haystack this has become and darnet, this puzzle will be pieced together sooner or later....

Looks like the Peregrine/Ambit collaboration is going on a year now and wonder how much PS Targeting has been vialed in the doors of Ambit up till now?

For those that were not aware: Peregrine did not give the order to remove this linkedin profile, like it seemed they had done with the 3 profiles that supports a new manufacturing facility in the works

Sr. Clinical Trial Manager
Ambit Biosciences
January 2014 – Present (1 year)

Peregrine Pharmaceuticals
Sr. Clinical Trial Manager
Peregrine Pharmaceuticals
August 2011 – Present (3 years 5 months)Tustin, CA

http://www.linkedin.com/pub/tom-sklenar/29/772/899

---------------------------

Ambit was also at ASH this past weekend and for Leukemia treatment...seems AML will benefit from a little PS Targeting so is there more that Ambit is not saying and playing by Peregrines new rules of restricting as much info as possible and small biotechs such as these must play by those rules or they get F'd. No, not that word......but Fargo'd!

Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH)

...
..
Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

http://www.erietvnews.com/story/27551187/ambit-biosciences-and-daiichi-sankyo-inc-announce-two-oral-presentations-and-one-poster-highlighting-quizartinib-to-be-presented-at-the-56th-annual

If it seems confusing, it certainly is! When you have "dozens of collaborations" and getting Bavituximab into the hands of as many as possible, this is one hell of an offense that will score many points in the months to come....and just hours away from seeing more shorts cover, gotta love it!

[biopharm]

Ambit / Peregrine collaboration.... trying to pull a needle from a haystack this has become and darnet, this puzzle will be pieced together sooner or later....

Read the link and at the very end I seen this portion below, not sure what that "..propietary CSF1R inhibitor program" would be or if any collaborators are involved and my guess is there is more to the story. I like how they place that at the very end... Peregrine like. Peregrine Falcon like... just swarming in the high skies above just waiting for that perfect moment for an appearance that is like a knife in the back to some other Big Pharma predators.

Quote:
June 12, 2014
...
..
..

....Quizartinib is also being studied in newly diagnosed patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

http://www.bizjournals.com/sanfrancisco/prnewswire/press_releases/California/2014/06/12/LA46577

Does anyone know where else Nathanael Gray came up before....lots of Grays lately....though Janne Pasi goes back to moderator for David Gerber back in Sept 2012

https://www.researchgate.net/profile/Nathanael_Gray

......In this collaboration, Dr. Gray's laboratory and the Dana-Farber Medicinal Chemistry Core will be joined by the laboratories of Pasi A. Jänne, M.D., Ph.D., and Kwok-Kin Wong, M.D., Ph.D. of the Thoracic Oncology Program and co-directors of the Belfer Institute for Applied Cancer Science at Dana-Farber and Professors at Harvard Medical School.
...
...
http://www.biospace.com/News/dana-farber-cancer-institute-and-astellas-pharma/352817